(NASDAQ: ERAS) Erasca's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.92%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.62%.
Erasca's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast ERAS's revenue for 2027 to be $9,496,141,573, with the lowest ERAS revenue forecast at $8,780,158,142, and the highest ERAS revenue forecast at $10,212,125,004. On average, 1 Wall Street analysts forecast ERAS's revenue for 2028 to be $32,905,736,124, with the lowest ERAS revenue forecast at $32,905,736,124, and the highest ERAS revenue forecast at $32,905,736,124.
In 2029, ERAS is forecast to generate $40,166,273,332 in revenue, with the lowest revenue forecast at $16,506,765,388 and the highest revenue forecast at $63,825,781,275.